Biomarker Characterization by MALDI-TOF/MS

Advances in Clinical Chemistry

Volumn 69, Issue , 2015, Pages 209-254

  Cho, Yi Tzu ^a   Su, Hung ^b   Wu, Wen Jeng ^c   Wu, Deng Chyang ^c,d   Hou, Ming Feng ^c   Kuo, Chao Hung ^c,d   Shiea, Jentaie ^b,c,d  

^a Yuh Ing Junior College of Health Care and Management   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Biofluids; Biomarkers; Clinical diagnosis; Immunoaffinity; Mass spectrometry; Matrix assisted laser desorption ionization time of flight mass spectrometry; Multivariate statistics; Nanomaterial

Indexed keywords

BIOLOGICAL MARKER; NANOMATERIAL;

CLINICAL CHEMISTRY; HUMAN; LIQUID LIQUID EXTRACTION; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID PHASE EXTRACTION;

BIOMARKERS; CHEMISTRY, CLINICAL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIQUID-LIQUID EXTRACTION; NANOSTRUCTURES; POLYMORPHISM, SINGLE NUCLEOTIDE; SOLID PHASE EXTRACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84945478141     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2015.01.001     Document Type: Chapter

References (320)

1. Shushan B. A review of clinical diagnostic applications of liquid chromatography-tandem mass spectrometry. Mass Spectrom. Rev. 2010, 29:930-944.
2. Parker C.E., Pearson T.W., Anderson N.L., Borchers C.H. Mass-spectrometry-based clinical proteomics-a review and prospective. Analyst 2010, 135:1830-1838.
3. Strathmann F.G., Hoofnagle A.N. Current and future applications of mass spectrometry to the clinical laboratory. Am. J. Clin. Pathol. 2011, 136:609-616.
4. Simoneit B.R. A review of current applications of mass spectrometry for biomarker/molecular tracer elucidation. Mass Spectrom. Rev. 2005, 24:719-765.
5. Bakry R., Rainer M., Huck C.W., Bonn G.K. Protein profiling for cancer biomarker discovery using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and infrared imaging: a review. Anal. Chim. Acta 2011, 690:26-34.
6. Pagotto U., Fanelli F., Pasquali R. Insights into tandem mass spectrometry for the laboratory endocrinology. Rev. Endocr. Metab. Disord. 2013, 14:141.
7. Carvalho V.M. The coming of age of liquid chromatography coupled to tandem mass spectrometry in the endocrinology laboratory. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012, 883-884:50-58.
8. Kushnir M.M., Rockwood A.L., Bergquist J. Liquid chromatography-tandem mass spectrometry applications in endocrinology. Mass Spectrom. Rev. 2010, 29:480-502.
9. Vogeser M., Parhofer K.G. Liquid chromatography tandem-mass spectrometry (LC-MS/MS)-technique and applications in endocrinology. Exp. Clin. Endocrinol. Diabetes 2007, 115:559-570.
10. Gstaiger M., Aebersold R. Applying mass spectrometry-based proteomics to genetics, genomics and network biology. Nat. Rev. Genet. 2009, 10:617-627.
11. Carpenter K.H., Wiley V. Application of tandem mass spectrometry to biochemical genetics and newborn screening. Clin. Chim. Acta 2002, 322:1-10.
12. Emonet S., Shah H.N., Cherkaoui A., Schrenzel J. Application and use of various mass spectrometry methods in clinical microbiology. Clin. Microbiol. Infect. 2010, 16:1604-1613.
13. Feng W.Y. Mass spectrometry in drug discovery: a current review. Curr. Drug Discov. Technol. 2004, 1:295-312.
14. Chen C.H. Review of a current role of mass spectrometry for proteome research. Anal. Chim. Acta 2008, 624:16-36.
15. Brash A.R., Draffan G.H., Clare R.A., Baillie T.A. A new method for the determination of the major metabolite of prostaglandin F2alpha in human urine based on stable isotope dilution and gas chromatography-mass spectrometry. Biochem. Soc. Trans. 1976, 4:706-708.
16. Min B.H., Garland W.A. Determination of clonazepam and its 7-amino metabolite in plasma and blood by gas chromatography-chemical ionization mass spectrometry. J. Chromatogr. 1977, 139:121-133.
17. Malcolm S.L., Marten T.R. Determination of debrisoquin and its 4-hydroxy metabolite in plasma by gas chromatography/mass spectrometry. Anal. Chem. 1976, 48:807-809.
18. Jakobs C. Prenatal diagnosis of inherited metabolic disorders by stable isotope dilution GC-MS analysis of metabolites in amniotic fluid: review of four years experience. J. Inherit. Metab. Dis. 1989, 12(Suppl. 2):267-270.
19. Niwa T. Metabolic profiling with gas chromatography-mass spectrometry and its application to clinical medicine. J. Chromatogr. 1986, 379:313-345.
20. Pasikanti K.K., Ho P.C., Chan E.C. Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 871:202-211.
21. Simon-Manso Y., Lowenthal M.S., Kilpatrick L.E., Sampson M.L., Telu K.H., Rudnick P.A., Mallard W.G., Bearden D.W., Schock T.B., Tchekhovskoi D.V., Blonder N., Yan X., Liang Y., Zheng Y., Wallace W.E., Neta P., Phinney K.W., Remaley A.T., Stein S.E. Metabolite profiling of a NIST Standard Reference Material for human plasma (SRM 1950): GC-MS, LC-MS, NMR, and clinical laboratory analyses, libraries, and web-based resources. Anal. Chem. 2013, 85:11725-11731.
22. Choi M.H., Chung B.C. Bringing GC-MS profiling of steroids into clinical applications. Mass Spectrom. Rev. 2014, 10.1002/mas.21436.
23. Christou C., Gika H.G., Raikos N., Theodoridis G. GC-MS analysis of organic acids in human urine in clinical settings: a study of derivatization and other analytical parameters. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2014, 964:195-201.
24. Gao X., Pujos-Guillot E., Sebedio J.L. Development of a quantitative metabolomic approach to study clinical human fecal water metabolome based on trimethylsilylation derivatization and GC/MS analysis. Anal. Chem. 2010, 82:6447-6456.
25. Bumler J., Jeger A. GC-MS in clinical toxicological analyses. Beitr. Gerichtl. Med. 1975, 33:177-181.
26. Papoutsis I., Mendonis M., Nikolaou P., Athanaselis S., Pistos C., Maravelias C., Spiliopoulou C. Development and validation of a simple GC-MS method for the simultaneous determination of 11 anticholinesterase pesticides in blood-clinical and forensic toxicology applications. J. Forensic Sci. 2012, 57:806-812.
27. Haller C.A., Stone J., Burke V., Branch J., Chen K., Gross S. Comparison of an automated and point-of-care immunoassay to GC-MS for urine oxycodone testing in the clinical laboratory. J. Anal. Toxicol. 2006, 30:106-111.
28. Philipp A.A., Meyer M.R., Wissenbach D.K., Weber A.A., Zoerntlein S.W., Zweipfenning P.G., Maurer H.H. Monitoring of kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology. Anal. Bioanal. Chem. 2011, 400:127-135.
29. Papoutsis S.A., Athanaselis P.D., Nikolaou C.M., Pistos C.A., Spiliopoulou C.P. Maravelias, development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology. J. Pharm. Biomed. Anal. 2010, 52:609-614.
30. Valentine J.L., Middleton R. GC-MS identification of sympathomimetic amine drugs in urine: rapid methodology applicable for emergency clinical toxicology. J. Anal. Toxicol. 2000, 24:211-222.
31. Nair H., Woo F., Hoofnagle A.N., Baird G.S. Clinical validation of a highly sensitive GC-MS platform for routine urine drug screening and real-time reporting of up to 212 drugs. J. Toxicol. 2013, 2013:1-7.
32. Mieth M., Schubert J.K., Groger T., Sabel B., Kischkel S., Fuchs P., Hein D., Zimmermann R., Miekisch W. Automated needle trap heart-cut GC/MS and needle trap comprehensive two-dimensional GC/TOF-MS for breath gas analysis in the clinical environment. Anal. Chem. 2010, 82:2541-2551.
33. Guallar-Hoyas C., Turner M.A., Blackburn G.J., Wilson I.D., Thomas C.L. A workflow for the metabolomic/metabonomic investigation of exhaled breath using thermal desorption GC-MS. Bioanalysis 2012, 4:2227-2237.
34. Ulanowska A., Trawinska E., Sawrycki P., Buszewski B. Chemotherapy control by breath profile with application of SPME-GC/MS method. J. Sep. Sci. 2012, 35:2908-2913.
35. Ulanowska A., Kowalkowski T., Hrynkiewicz K., Jackowski M., Buszewski B. Determination of volatile organic compounds in human breath for Helicobacter pylori detection by SPME-GC/MS. Biomed. Chromatogr. 2011, 25:391-397.
36. King J., Mochalski P., Kupferthaler A., Unterkofler K., Koc H., Filipiak W., Teschl S., Hinterhuber H., Amann A. Dynamic profiles of volatile organic compounds in exhaled breath as determined by a coupled PTR-MS/GC-MS study. Physiol. Meas. 2010, 31:1169-1184.
37. Poli D., Goldoni M., Corradi M., Acampa O., Carbognani P., Internullo E., Casalini A., Mutti A. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2010, 878:2643-2651.
38. Plebani C., Tranfo G., Salerno A., Panebianco A., Marcelloni A.M. An optimized sampling and GC-MS analysis method for benzene in exhaled breath, as a biomarker for occupational exposure. Talanta 1999, 50:409-412.
39. Van den Velde S., Nevens F., Van Hee P., van Steenberghe D., Quirynen M. GC-MS analysis of breath odor compounds in liver patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 875:344-348.
40. Dang N.A., Janssen H.G., Kolk A.H. Rapid diagnosis of TB using GC-MS and chemometrics. Bioanalysis 2013, 5:3079-3097.
41. Wu H.F., Yen J.H. Dynamic liquid phase nanoextraction coupled to GC/MS for rapid analysis of methoxyacetophenone and anisaldehyde isomers in urine. J. Sep. Sci. 2008, 31:2295-2302.
42. Slater C., Ling S.C., Preston T., Weaver L.T. Analysis of 13C-mixed triacylglycerol in stool by bulk (EA-IRMS) and compound specific (GC/MS) methods. Isotopes Environ. Health Stud. 2002, 38:79-86.
43. Cordell R.L., Pandya H., Hubbard M., Turner M.A., Monks P.S. GC-MS analysis of ethanol and other volatile compounds in micro-volume blood samples-quantifying neonatal exposure. Anal. Bioanal. Chem. 2013, 405:4139-4147.
44. Watanabe K., Fujita H., Hasegawa K., Gonmori K., Suzuki O. GC/MS with post-column switching for large volume injection of headspace samples: sensitive determination of volatile organic compounds in human whole blood and urine. Anal. Chem. 2011, 83:1475-1479.
45. Wu A.H., French D. Implementation of liquid chromatography/mass spectrometry into the clinical laboratory. Clin. Chim. Acta 2013, 420:4-10.
46. Becker S., Kortz L., Helmschrodt C., Thiery J., Ceglarek U. LC-MS-based metabolomics in the clinical laboratory. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012, 883-884:68-75.
47. Grebe S.K., Singh R.J. LC-MS/MS in the clinical laboratory-where to from here?. Clin. Biochem. Rev. 2011, 32:5-31.
48. Leung K.S., Fong B.M. LC-MS/MS in the routine clinical laboratory: has its time come?. Anal. Bioanal. Chem. 2014, 406:2289-2301.
49. Lu X., Zhao X., Bai C., Zhao C., Lu G., Xu G. LC-MS-based metabonomics analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 866:64-76.
50. Torsetnes S.B., Levernaes M.S., Broughton M.N., Paus E., Halvorsen T.G., Reubsaet L. Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS. Anal. Chem. 2014, 86:6983-6992.
51. Lin T., Pan K., Mordenti J., Pan L. In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography. J. Pharm. Sci. 2007, 96:2485-2493.
52. Bhatt J., Subbaiah G., Kambli S., Shah B., Patel M., Saxena A., Baliga A., Nigam S., Parekh H., Yadav G. A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 852:374-381.
53. Ketha H., Kaur S., Grebe S.K., Singh R.J. Clinical applications of LC-MS sex steroid assays: evolution of methodologies in the 21st century. Curr. Opin. Endocrinol. 2014, 21:217-226.
54. Rauh M. Steroid measurement with LC-MS/MS. Application examples in pediatrics. J. Steroid Biochem. 2010, 121:520-527.
55. Couchman L., Vincent R.P., Ghataore L., Moniz C.F., Taylor N.F. Challenges and benefits of endogenous steroid analysis by LC-MS/MS. Bioanalysis 2011, 3:2549-2572.
56. de Jong W.H., de Vries E.G., Kema I.P. Current status and future developments of LC-MS/MS in clinical chemistry for quantification of biogenic amines. Clin. Biochem. 2011, 44:95-103.
57. Gallardo E., Barroso M., Queiroz J.A. LC-MS: a powerful tool in workplace drug testing. Drug Test. Anal. 2009, 1:109-115.
58. Poquette M.A., Lensmeyer G.L., Doran T.C. Effective use of liquid chromatography-mass spectrometry (LC/MS) in the routine clinical laboratory for monitoring sirolimus, tacrolimus, and cyclosporine. Ther. Drug Monit. 2005, 27:144-150.
59. Lehotay D.C., Hall P., Lepage J., Eichhorst J.C., Etter M.L., Greenberg C.R. LC-MS/MS progress in newborn screening. Clin. Biochem. 2011, 44:21-31.
60. Johnson D.W. Contemporary clinical usage of LC/MS: analysis of biologically important carboxylic acids. Clin. Biochem. 2005, 38:351-361.
61. Leung K.S., Fong B.M., Tsoi Y.K. Analytical challenges: determination of tetrodotoxin in human urine and plasma by LC-MS/MS. Mar. Drugs 2011, 9:2291-2303.
62. Hsu S.A., Soldo J., Gupta M. Evaluation of two automated immunoassays for 25-OH vitamin D: comparison against LC-MS/MS. J. Steroid Biochem. Mol. Biol. 2013, 136:139-145.
63. Gilliland D.L., Black C.K., Denison J.E., Seipelt C.T. Simultaneous determination of vitamins D2 and D3 by LC-MS/MS in infant formula and adult nutritionals: First Action 2011.13. J. AOAC Int. 2012, 95:583-587.
64. Heller M., Schlappritzi E., Stalder D., Nuoffer J.M., Haeberli A. Compositional protein analysis of high density lipoproteins in hypercholesterolemia by shotgun LC-MS/MS and probabilistic peptide scoring. Mol. Cell. Proteomics 2007, 6:1059-1072.
65. Turtoi A., Mazzucchelli G.D., De Pauw E. Isotope coded protein label quantification of serum proteins-comparison with the label-free LC-MS and validation using the MRM approach. Talanta 2010, 80:1487-1495.
66. Clough T., Thaminy S., Ragg S., Aebersold R., Vitek O. Statistical protein quantification and significance analysis in label-free LC-MS experiments with complex designs. BMC Bioinformatics 2012, 13(Suppl. 16):S6.
67. Wan C., Liu J., Fong V., Lugowski A., Stoilova S., Bethune-Waddell D., Borgeson B., Havugimana P.C., Marcotte E.M., Emili A. ComplexQuant: high-throughput computational pipeline for the global quantitative analysis of endogenous soluble protein complexes using high resolution protein HPLC and precision label-free LC/MS/MS. J. Proteomics 2013, 81:102-111.
68. Levin Y., Schwarz E., Wang L., Leweke F.M., Bahn S. Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. J. Sep. Sci. 2007, 30:2198-2203.
69. Lee S.W., Kim I.J., Jeong B.Y., Choi M.H., Kim J.Y., Kwon K.H., Lee J.W., Yu A., Shin M.G. Use of MDLC-DIGE and LC-MS/MS to identify serum biomarkers for complete remission in patients with acute myeloid leukemia. Electrophoresis 2012, 33:1863-1872.
70. Levin Y., Wang L., Ingudomnukul E., Schwarz E., Baron-Cohen S., Palotas A., Bahn S. Real-time evaluation of experimental variation in large-scale LC-MS/MS-based quantitative proteomics of complex samples. J. Chromatogr B. Analyt. Technol. Biomed. Life Sci. 2009, 877:1299-1305.
71. Lee S.W., Kim I.J., Jeong B.Y., Choi M.H., Kim J.Y., Kwon K.H., Lee J.W., Yu A., Shin M.G. Use of MDLC-DIGE and LC-MS/MS to identify serum biomarkers for complete remission in patients with acute myeloid leukemia. Electrophoresis 2012, 33:1863-1872.
72. Wei B.R., Simpson R.M., Johann D.J., Dwyer J.E., Prieto D.A., Kumar M., Ye X., Luke B., Shive H.R., Webster J.D., Hoover S.B., Veenstra T.D., Blonder J. Proteomic profiling of H-Ras-G12V induced hypertrophic cardiomyopathy in transgenic mice using comparative LC-MS analysis of thin fresh-frozen tissue sections. J. Proteome Res. 2012, 11:1561-1570.
73. Su X., Lucas D.M., Zhang L., Xu H., Zabrouskov V., Davis M.E., Knapp A.R., Young D.C., Payne P.R., Parthun M.R., Marcucci G., Grever M.R., Byrd J.C., Freitas M.A. Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia. Proteomics 2009, 9:1197-1206.
74. Shaikh A., Seegmiller J.C., Borland T.M., Burns B.E., Ladwig P.M., Singh R.J., Kumar R., Larson T.S., Lieske J.C. Comparison between immunoturbidimetry, size-exclusion chromatography, and LC-MS to quantify urinary albumin. Clin. Chem. 2008, 54:1504-1510.
75. Couchman L., Taylor D.R., Krastins B., Lopez M.F., Moniz C.F. LC-MS candidate reference methods for the harmonisation of parathyroid hormone (PTH) measurement: a review of recent developments and future considerations. Clin. Chem. Lab. Med. 2014, 52:1251-1263.
76. Wolff F., Deleers M., Melot C., Gulbis B., Cotton F. Hepcidin-25: measurement by LC-MS/MS in serum and urine, reference ranges and urinary fractional excretion. Clin. Chim. Acta 2013, 423:99-104.
77. Li H., Rose M.J., Tran L., Zhang J., Miranda L.P., James C.A., Sasu B.J. Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J. Pharmacol. Toxicol. Methods 2009, 59:171-180.
78. Kakiyama G., Muto A., Takei H., Nittono H., Murai T., Kurosawa T., Hofmann A.F., Pandak W.M., Bajaj J.S. A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS. J. Lipid Res. 2014, 55:978-990.
79. Stettner D., Bujak-Gizycka B., Olszanecki R., Rytlewski K., Huras H., Korbut R. Assessment of angiotensin I metabolism in the human placenta using an LC/MS method. Folia Med. Cracov. 2013, 53:31-39.
80. Chappell D.L., McAvoy T., Weiss B., Weiner R., Laterza O.F. Development and validation of an ultra-sensitive method for the measurement of plasma renin activity in human plasma via LC-MS/MS. Bioanalysis 2012, 4:2843-2850.
81. Takats Z., Wiseman J.M., Cooks R.G. Ambient mass spectrometry using desorption electrospray ionization (DESI): instrumentation, mechanisms and applications in forensics, chemistry, and biology. J. Mass Spectrom. 2005, 40:1261-1275.
82. Cooks R.G., Ouyang Z., Takats Z., Wiseman J.M. Detection technologies. Ambient mass spectrometry. Science 2006, 311:1566-1570.
83. Alberici R.M., Simas R.C., Sanvido G.B., Romao W., Lalli P.M., Benassi M., Cunha I.B., Eberlin M.N. Ambient mass spectrometry: bringing MS into the "real world". Anal. Bioanal. Chem. 2010, 398:265-294.
84. Huang M.Z., Yuan C.H., Cheng S.C., Cho Y.T., Shiea J. Ambient ionization mass spectrometry. Annu. Rev. Anal. Chem. 2010, 3:43-65.
85. Weston D.J. Ambient ionization mass spectrometry: current understanding of mechanistic theory; analytical performance and application areas. Analyst 2010, 135:661-668.
86. Huang M.Z., Cheng S.C., Cho Y.T., Shiea J. Ambient ionization mass spectrometry: a tutorial. Anal. Chim. Acta 2011, 702:1-15.
87. Yao Z.P. Characterization of proteins by ambient mass spectrometry. Mass Spectrom. Rev. 2012, 31:437-447.
88. Li L.P., Feng B.S., Yang J.W., Chang C.L., Bai Y., Liu H.W. Applications of ambient mass spectrometry in high-throughput screening. Analyst 2013, 138:3097-3103.
89. Shiea J., Yuan C.H., Huang M.Z., Cheng S.C., Ma Y.L., Tseng W.L., Chang H.C., Hung W.C. Detection of native protein ions in aqueous solution under ambient conditions by electrospray laser desorption/ionization mass spectrometry. Anal. Chem. 2008, 80:4845-4852.
90. Corso G., D'Apolito O., Gelzo M., Paglia G., Dello Russo A. A powerful couple in the future of clinical biochemistry: in situ analysis of dried blood spots by ambient mass spectrometry. Bioanalysis 2010, 2:1883-1891.
91. Corso G., Paglia G., Garofalo D., D'Apolito O. Neutral loss analysis of amino acids by desorption electrospray ionization using an unmodified tandem quadrupole mass spectrometer. Rapid Commun. Mass Spectrom. 2007, 21:3777-3784.
92. Wiseman J.M., Evans C.A., Bowen C.L., Kennedy J.H. Direct analysis of dried blood spots utilizing desorption electrospray ionization (DESI) mass spectrometry. Analyst 2010, 135:720-725.
93. Crawford E., Gordon J., Wu J.T., Musselman B., Liu R., Yu S. Direct analysis in real time coupled with dried spot sampling for bioanalysis in a drug-discovery setting. Bioanalysis 2011, 3:1217-1226.
94. Su Y., Wang H., Liu J.J., Wei P., Cooks R.G., Ouyang Z. Quantitative paper spray mass spectrometry analysis of drugs of abuse. Analyst 2013, 138:4443-4447.
95. Zhang Z.P., Xu W., Manicke N.E., Cooks R.G., Ouyang Z. Silica coated paper substrate for paper-spray analysis of therapeutic drugs in dried blood spots. Anal. Chem. 2012, 84:931-938.
96. Rath C.M., Yang J.Y., Alexandrov T., Dorrestein P.C. Data-independent microbial metabolomics with ambient ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 2013, 24:1167-1176.
97. Dill A.L., Eberlin L.S., Costa A.B., Zheng C., Ifa D.R., Cheng L., Masterson T.A., Koch M.O., Vitek O., Cooks R.G. Multivariate statistical identification of human bladder carcinomas using ambient ionization imaging mass spectrometry. Chemistry 2011, 17:2897-2902.
98. Pirro V., Eberlin L.S., Oliveri P., Cooks R.G. Interactive hyperspectral approach for exploring and interpreting DESI-MS images of cancerous and normal tissue sections. Analyst 2012, 137:2374-2380.
99. Cooks R.G., Manicke N.E., Dill A.L., Ifa D.R., Eberlin L.S., Costa A.B., Wang H., Huang G.M., Zheng O.Y. New ionization methods and miniature mass spectrometers for biomedicine: DESI imaging for cancer diagnostics and paper spray ionization for therapeutic drug monitoring. Faraday Discuss. 2011, 149:247-267.
100. Dill A.L., Ifa D.R., Manicke N.E., Ouyang Z., Cooks R.G. Mass spectrometric imaging of lipids using desorption electrospray ionization. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:2883-2889.
101. Cooks R.G., Mueller T. Through a glass darkly: glimpses into the future of mass spectrometry. Mass Spectrom. 2013, 2:S0001.
102. J. Shiea, Mass spectrometric methods and mass spectrometer for analyzing a vaporized sample, US patent 2010, US7,750,291 B2.
103. Meier L., Schmid S., Berchtold C., Zenobi R. Contribution of liquid-phase and gas-phase ionization in extractive electrospray ionization mass spectrometry of primary amines. Eur. J. Mass Spectrom. 2011, 17:345-351.
104. Gu H., Xu N., Chen H. Direct analysis of biological samples using extractive electrospray ionization mass spectrometry (EESI-MS). Anal. Bioanal. Chem. 2012, 403:2145-2153.
105. Ding J., Yang S., Liang D., Chen H., Wu Z., Zhang L., Ren Y. Development of extractive electrospray ionization ion trap mass spectrometry for in vivo breath analysis. Analyst 2009, 134:2040-2050.
106. Zhu J., Jimenez-Diaz J., Bean H.D., Daphtary N.A., Aliyeva M.I., Lundblad L.K., Hill J.E. Robust detection of P. aeruginosa and S. aureus acute lung infections by secondary electrospray ionization-mass spectrometry (SESI-MS) breathprinting: from initial infection to clearance. J. Breath Res. 2013, 7:037106.
107. Zhu J., Bean H.D., Jimenez-Diaz J., Hill J.E. Secondary electrospray ionization-mass spectrometry (SESI-MS) breathprinting of multiple bacterial lung pathogens, a mouse model study. J. Appl. Physiol. 2013, 114:1544-1549.
108. Zhu J., Bean H.D., Wargo M.J., Leclair L.W., Hill J.E. Detecting bacterial lung infections: in vivo evaluation of in vitro volatile fingerprints. J. Breath Res. 2013, 7:016003.
109. Sinues P.M., Kohler M., Zenobi R. Monitoring diurnal changes in exhaled human breath. Anal. Chem. 2013, 85:369-373.
110. Bean H.D., Zhu J., Hill J.E. Characterizing bacterial volatiles using secondary electrospray ionization mass spectrometry (SESI-MS). J. Vis. Exp. 2011, 52:e2664.
111. Martinez-Lozano P., Zingaro L., Finiguerra A., Cristoni S. Secondary electrospray ionization-mass spectrometry: breath study on a control group. J. Breath Res. 2011, 5:016002.
112. Balog J., Szaniszio T., Schaefer K.C., Denes J., Lopata A., Godorhazy L., Szalay D., Balogh L., Sasi-Szabo L., Toth M., Takats Z. Identification of biological tissues by rapid evaporative ionization mass spectrometry. Anal. Chem. 2010, 82:7343-7350.
113. Balog J., Sasi-Szabo L., Kinross J., Lewis M.R., Muirhead L.J., Veselkov K., Mirnezami R., Dezso B., Damjanovich L., Darzi A., Nicholson J.K., Takats Z. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci. Transl. Med. 2013, 5:194ra93.
114. Hillenkamp F., Karas M. Mass-spectrometry of peptides and proteins by matrix-assisted ultraviolet-laser desorption ionization. Methods Enzymol. 1990, 193:280-295.
115. Nelson R.W., Dogruel D., Williams P. Mass determination of human-immunoglobulin IgM using matrix-assisted laser-desorption ionization time-of-flight mass-spectrometry. Rapid Commun. Mass Spectrom. 1994, 8:627-631.
116. Cramer R., Gobom J., Nordhoff E. High-throughput proteomics using matrix-assisted laser desorption/ionization mass spectrometry. Expert Rev. Proteomics 2005, 2:407-420.
117. Kaufmann R. Matrix-assisted laser-desorption ionization (MALDI) mass-spectrometry-a novel analytical tool in molecular-biology and biotechnology. J. Biotechnol. 1995, 41:155-175.
118. Stuhler K., Meyer H.E. MALDI: more than peptide mass fingerprints. Curr. Opin. Mol. Ther. 2004, 6:239-248.
119. Umemura H., Kodera Y., Nomura F. Effects of humidity on the dried-droplet sample preparation for MALDI-TOF MS peptide profiling. Clin. Chim. Acta 2010, 411:2109-2111.
120. Jaskolla T.W., Karas M., Roth U., Steinert K., Menzel C., Reihs K. Comparison between vacuum sublimed matrices and conventional dried droplet preparation in MALDI-TOF mass spectrometry. J. Am. Soc. Mass Spectrom. 2009, 20:1104-1114.
121. Garaguso I., Borlak J. Matrix layer sample preparation: an improved MALDI-MS peptide analysis method for proteomic studies. Proteomics 2008, 8:2583-2595.
122. Keller B.O., Li L. Three-layer matrix/sample preparation method for MALDI MS analysis of low nanomolar protein samples. J. Am. Soc. Mass Spectrom. 2006, 17:780-785.
123. Zheng J., Li N., Ridyard M., Dai H., Robbins S.M., Li L. Simple and robust two-layer matrix/sample preparation method for MALDI MS/MS analysis of peptides. J. Proteome Res. 2005, 4:1709-1716.
124. Fenselau C. MALDI MS and strategies for protein analysis. Anal. Chem. 1997, 69:A661-A665.
125. Bonk T., Humeny A. MALDI-TOF-MS analysis of protein and DNA. Neuroscientist 2001, 7:6-12.
126. Harvey D.J. Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2007-2008. Mass Spectrom. Rev. 2012, 31:183-311.
127. Pusch W., Flocco M.T., Leung S.M., Thiele H., Kostrzewa M. Mass spectrometry-based clinical proteomics. Pharmacogenomics 2003, 4:463-476.
128. Hendriks M.M., Smit S., Akkermans W.L., Reijmers T.H., Eilers P.H., Hoefsloot H.C., Rubingh C.M., de Koster C.G., Aerts J.M., Smilde A.K. How to distinguish healthy from diseased? Classification strategy for mass spectrometry-based clinical proteomics. Proteomics 2007, 7:3672-3680.
129. Iwadate Y. Clinical proteomics in cancer research-promises and limitations of current two-dimensional gel electrophoresis. Curr. Med. Chem. 2008, 15:2393-2400.
130. Pusch W., Kostrzewa M. Application of MALDI-TOF mass spectrometry in screening and diagnostic research. Curr. Pharm. Des. 2005, 11:2577-2591.
131. Marvin L.F., Roberts M.A., Fay L.B. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. Clin. Chim. Acta 2003, 337:11-21.
132. Croxatto A., Prod'hom G., Greub G. Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology. FEMS Microbiol. Rev. 2012, 36:380-407.
133. Griffin T.J., Smith L.M. Single-nucleotide polymorphism analysis by MALDI-TOF mass spectrometry. Trends Biotechnol. 2000, 18:77-84.
134. Schwamborn K., Caprioli R.M. MALDI imaging mass spectrometry-painting molecular pictures. Mol. Oncol. 2010, 4:529-538.
135. Cho Y.T., Su H., Huang T.L., Chen H.C., Wu W.J., Wu P.C., Wu D.C., Shiea J. Matrix-assisted laser desorption ionization/time-of-flight mass spectrometry for clinical diagnosis. Clin. Chim. Acta 2013, 415:266-275.
136. Fournier P.E., Drancourt M., Colson P., Rolain J.M., La Scola B., Raoult D. Modern clinical microbiology: new challenges and solutions. Nat. Rev. Microbiol. 2013, 11:574-585.
137. Sauer S., Kliem M. Mass spectrometry tools for the classification and identification of bacteria. Nat. Rev. Microbiol. 2010, 8:74-82.
138. Wieser A., Schneider L., Jung J., Schubert S. MALDI-TOF MS in microbiological diagnostics-identification of microorganisms and beyond (mini review). Appl. Microbiol. Biotechnol. 2012, 93:965-974.
139. Carbonnelle E., Mesquita C., Bille E., Day N., Dauphin B., Beretti J.L., Ferroni A., Gutmann L., Nassif X. MALDI-TOF mass spectrometry tools for bacterial identification in clinical microbiology laboratory. Clin. Biochem. 2011, 44:104-109.
140. Clark A.E., Kaleta E.J., Arora A., Wolk D.M. Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clin. Microbiol. Rev. 2013, 26:547-603.
141. Ho Y.P., Reddy P.M. Advances in mass spectrometry for the identification of pathogens. Mass Spectrom. Rev. 2011, 30:1203-1224.
142. Seng P., Rolain J.M., Fournier P.E., La Scola B., Drancourt M., Raoult D. MALDI-TOF-mass spectrometry applications in clinical microbiology. Future Microbiol. 2010, 5:1733-1754.
143. Cobo F. Application of MALDI-TOF mass spectrometry in clinical virology: a review. Open Virol. J. 2013, 7:84-90.
144. Fenselau C., Demirev P.A. Characterization of intact microorganisms by MALDI mass spectrometry. Mass Spectrom. Rev. 2001, 20:157-171.
145. Gao X., Tan B.H., Sugrue R.J., Tang K. MALDI mass spectrometry for nucleic acid analysis. Top. Curr. Chem. 2013, 331:55-77.
146. Sauer S. Typing of single nucleotide polymorphisms by MALDI mass spectrometry: principles and diagnostic applications. Clin. Chim. Acta 2006, 363:95-105.
147. Tost J., Gut I.G. Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin. Biochem. 2005, 38:335-350.
148. Pusch W., Wurmbach J.H., Thiele H., Kostrzewa M. MALDI-TOF mass spectrometry-based SNP genotyping. Pharmacogenomics 2002, 3:537-548.
149. Leushner J. MALDI TOF mass spectrometry: an emerging platform for genomics and diagnostics. Expert Rev. Mol. Diagn. 2001, 1:11-18.
150. Tang K., Oeth P., Kammerer S., Denissenko M.F., Ekblom J., Jurinke C., van den Boom D., Braun A., Cantor C.R. Mining disease susceptibility genes through SNP analyses and expression profiling using MALDI-TOF mass spectrometry. J. Proteome Res. 2004, 3:218-227.
151. Jurinke C., Oeth P., van den Boom D. MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis. Mol. Biotechnol. 2004, 26:147-164.
152. Chaurand P., Norris J.L., Cornett D.S., Mobley J.A., Caprioli R.M. New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J. Proteome Res. 2006, 5:2889-2900.
153. Cornett D.S., Reyzer M.L., Chaurand P., Caprioli R.M. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat. Methods 2007, 4:828-833.
154. Goodwin R.J., Pennington S.R., Pitt A.R. Protein and peptides in pictures: imaging with MALDI mass spectrometry. Proteomics 2008, 8:3785-3800.
155. Li L., Sweedler J.V. Peptides in the brain: mass spectrometry-based measurement approaches and challenges. Annu. Rev. Anal. Chem. 2008, 1:451-483.
156. Walch A., Rauser S., Deininger S.O., Hofler H. MALDI imaging mass spectrometry for direct tissue analysis: a new frontier for molecular histology. Histochem. Cell Biol. 2008, 130:421-434.
157. Franck J., Arafah K., Elayed M., Bonnel D., Vergara D., Jacquet A., Vinatier D., Wisztorski M., Day R., Fournier I., Salzet M. MALDI imaging mass spectrometry: state of the art technology in clinical proteomics. Mol. Cell. Proteomics 2009, 8:2023-2033.
158. Balluff B., Schone C., Hofler H., Walch A. MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications. Histochem. Cell Biol. 2011, 136:227-244.
159. Boggio K.J., Obasuyi E., Sugino K., Nelson S.B., Agar N.Y., Agar J.N. Recent advances in single-cell MALDI mass spectrometry imaging and potential clinical impact. Expert Rev. Proteomics 2011, 8:591-604.
160. Castellino S., Groseclose M.R., Wagner D. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. Bioanalysis 2011, 3:2427-2441.
161. Chaurand P., Cornett D.S., Angel P.M., Caprioli R.M. From whole-body sections down to cellular level, multiscale imaging of phospholipids by MALDI mass spectrometry. Mol. Cell Proteomic. 2011, 10. O110.004259.
162. Gemoll T., Roblick U.J., Habermann J.K. MALDI mass spectrometry imaging in oncology (review). Mol. Med. Rep. 2011, 4:1045-1051.
163. Hsieh Y., Chen J., Korfmacher W.A. Mapping pharmaceuticals in tissues using MALDI imaging mass spectrometry. J. Pharmacol. Toxicol. Methods 2007, 55:193-200.
164. Wang H.Y., Lo L.H., Tyan Y.C., Chen H.C., Yang M.H., Chen T.Y., Wang H.Y.J., Shiea J. The study of the distribution of melamine in rat renal tissues by imaging mass spectrometry. Anal. Methods 2010, 2:1974-1981.
165. Gustafsson J.O., Oehler M.K., Ruszkiewicz A., McColl S.R., Hoffmann P. MALDI Imaging Mass Spectrometry (MALDI-IMS)-application of spatial proteomics for ovarian cancer classification and diagnosis. Int. J. Mol. Sci. 2011, 12:773-794.
166. Seeley E.H., Caprioli R.M. MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives. Trends Biotechnol. 2011, 29:136-143.
167. Balluff B., Rauser S., Ebert M.P., Siveke J.T., Hofler H., Walch A. Direct molecular tissue analysis by MALDI imaging mass spectrometry in the field of gastrointestinal disease. Gastroenterology 2012, 143:544-549.
168. Chatterji B., Pich A. MALDI imaging mass spectrometry and analysis of endogenous peptides. Expert Rev. Proteomics 2013, 10:381-388.
169. Neubert P., Walch A. Current frontiers in clinical research application of MALDI imaging mass spectrometry. Expert Rev. Proteomics 2013, 10:259-273.
170. Schone C., Hofler H., Walch A. MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. Clin. Biochem. 2013, 46:539-545.
171. Gessel M.M., Norris J.L., Caprioli R.M. MALDI imaging mass spectrometry: spatial molecular analysis to enable a new age of discovery. J. Proteomics 2014, 107:71-82.
172. Gorzolka K., Walch A. MALDI mass spectrometry imaging of formalin-fixed paraffin-embedded tissues in clinical research. Histol. Histopathol. 2014, 29:1365-1376.
173. Calvano C.D., Aresta A., Iacovone M., De Benedetto G.E., Zambonin C.G., Battaglia M., Ditonno P., Rutigliano M., Bettocchi C. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles. J. Pharm. Biomed. Anal. 2010, 51:907-914.
174. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem. 2007, 53:852-858.
175. Zerefos P., Prados J., Kossida S., Kalousis A., Vlahou A. Sample preparation and bioinformatics in MALDI profiling of urinary proteins. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 853:20-30.
176. Olson M.T., Epstein J.A., Sackett D.L., Yergey A.L. Production of reliable MALDI spectra with quality threshold clustering of replicates. J. Am. Soc. Mass Spectrom. 2011, 22:969-975.
177. Anderson N.L., Razavi M., Pearson T.W., Kruppa G., Paape R., Suckau D. Precision of heavy-light peptide ratios measured by MALDI-TOF mass spectrometry. J. Proteome Res. 2012, 11:1868-1878.
178. Tracy M.B., Chen H., Weaver D.M., Malyarenko D.I., Sasinowski M., Cazares L.H., Drake R.R., Semmes O.J., Tracy E.R., Cooke W.E. Precision enhancement of MALDI-TOF MS using high resolution peak detection and label-free alignment. Proteomics 2008, 8:1530-1538.
179. Holt G.E., Schwartz H.S., Caldwell R.L. Proteomic profiling in musculoskeletal oncology by MALDI mass spectrometry. Clin. Orthop. Relat. Res. 2006, 450:105-110.
180. Leung S.M., Pitts R.L. A novel approach using MALDI-TOF/TOF mass spectrometry and prestructured sample supports (AnchorChip Technology) for proteomic profiling and protein identification. Methods Mol. Biol. 2008, 441:57-70.
181. Nelsestuen G.L., Harvey S.B., Zhang Y., Kasthuri R.S., Sinaiko A.R., Ely E.W., Bernard G.R., Homoncik M., Jilma B. Top-down proteomic analysis by MALDI-TOF profiling: concentration-independent biomarkers. Proteomics Clin. Appl. 2008, 2:158-166.
182. Karbassi I.D., Nyalwidhe J.O., Wilkins C.E., Cazares L.H., Lance R.S., Semmes O.J., Drake R.R. Proteomic expression profiling and identification of serum proteins using immobilized trypsin beads with MALDI-TOF/TOF. J. Proteome Res. 2009, 8:4182-4192.
183. Sui W., Dai Y., Zhang Y., Chen J., Liu H., Huang H. Proteomic profiling of uremia in serum using magnetic bead-based sample fractionation and MALDI-TOF MS. Ren. Fail. 2010, 32:1153-1159.
184. Sui W., Huang L., Dai Y., Chen J., Yan Q., Huang H. Proteomic profiling of renal allograft rejection in serum using magnetic bead-based sample fractionation and MALDI-TOF MS. Clin. Exp. Med. 2010, 10:259-268.
185. Sui W., Dai Y., Zhang Y., Chen J., Liu H., Huang H. Proteomic profiling of nephrotic syndrome in serum using magnetic bead based sample fractionation & MALDI-TOF MS. Indian J. Med. Res. 2012, 135:305-311.
186. Albalat A., Husi H., Stalmach A., Schanstra J.P., Mischak H. Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications. Bioanalysis 2014, 6:247-266.
187. Albrethsen J. The first decade of MALDI protein profiling: a lesson in translational biomarker research. J. Proteomics 2011, 74:765-773.
188. Mari A., Montoro P., Pizza C., Piacente S. Liquid chromatography tandem mass spectrometry determination of chemical markers and principal component analysis of Vitex agnus-castus L. fruits (Verbenaceae) and derived food supplements. J. Pharm. Biomed. Anal. 2012, 70:224-230.
189. Gerbig S., Takats Z. Analysis of triglycerides in food items by desorption electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24:2186-2192.
190. Camargo M., Intasqui P., Bruna de Lima C., Montani D.A., Nichi M., Pilau E.J., Gozzo F.C., Lo Turco E.G., Bertolla R.P. MALDI-TOF fingerprinting of seminal plasma lipids in the study of human male infertility. Lipids 2014, 49:943-956.
191. Shao C., Tian Y., Dong Z., Gao J., Gao Y., Jia X., Guo G., Wen X., Jiang C., Zhang X. The use of principal component analysis in MALDI-TOF MS: a powerful tool for establishing a mini-optimized proteomic profile. Am. J. Biomed. Sci. 2012, 4:85-101.
192. Cole L.M., Djidja M.C., Bluff J., Claude E., Carolan V.A., Paley M., Tozer G.M., Clench M.R. Investigation of protein induction in tumour vascular targeted strategies by MALDI MSI. Methods 2011, 54:442-453.
193. M'Koma A.E., Blum D.L., Norris J.L., Koyama T., Billheimer D., Motley S., Ghiassi M., Ferdowsi N., Bhowmick I., Chang S.S., Fowke J.H., Caprioli R.M., Bhowmick N.A. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem. Biophys. Res. Commun. 2007, 353:829-834.
194. Deininger S.O., Ebert M.P., Futterer A., Gerhard M., Rocken C. MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. J. Proteome Res. 2008, 7:5230-5236.
195. Djidja M.C., Claude E., Snel M.F., Francese S., Scriven P., Carolan V., Clench M.R. Novel molecular tumour classification using MALDI-mass spectrometry imaging of tissue micro-array. Anal. Bioanal. Chem. 2010, 397:587-601.
196. Pallua J.D., Schaefer G., Seifarth C., Becker M., Meding S., Rauser S., Walch A., Handler M., Netzer M., Popovscaia M., Osl M., Baumgartner C., Lindner H., Kremser L., Sarg B., Bartsch G., Huck C.W., Bonn G.K., Klocker H. MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer. J. Proteomics 2013, 91:500-514.
197. Ward J.H. Hierarchical grouping to optimize an objective function. J. Am. Stat. Assoc. 1963, 58:236-244.
198. Chiang Y.Y., Cho Y.T., Shiea J. The study of breast cancer tissues by imaging mass spectrometry 2011.
199. Simerville J.A., Maxted W.C., Pahira J.J. Urinalysis: a comprehensive review. Am. Fam. Physician 2005, 71:1153-1162.
200. Shiea J., Cho Y.T., Lin Y.H., Chang C.W., Lo L.H., Lee Y.C., Ke H.L., Wu W.J., Wu D.C. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to rapidly screen for albuminuria. Rapid Commun. Mass Spectrom. 2008, 22:3754-3760.
201. Cho Y.T., Chen Y.S., Hu J.L., Shiea J., Yeh S.M., Chen H.C., Lee Y.C., Wu D.C. The study of interferences for diagnosing albuminuria by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. Clin. Chim. Acta 2012, 413:875-882.
202. Winchester B. Lysosomal metabolism of glycoproteins. Glycobiology 2005, 15:1R-15R.
203. Bonesso L., Piraud M., Caruba C., Van Obberghen E., Mengual R., Hinault C. Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry. Orphanet J. Rare Dis. 2014, 9:19.
204. Xia B., Asif G., Arthur L., Pervaiz M.A., Li X., Liu R., Cummings R.D., He M. Oligosaccharide analysis in urine by MALDI-TOF mass spectrometry for the diagnosis of lysosomal storage diseases. Clin. Chem. 2013, 59:1357-1368.
205. Lapolla A., Fedele D., Aronica R., Garbeglio M., D'Alpaos M., Seraglia R., Traldi P. The in vivo glyco-oxidation of alpha- and beta-globins investigated by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun. Mass Spectrom. 1996, 10:1133-1135.
206. Lapolla A., Fedele D., Aronica R., Garbeglio M., D'Alpaos M., Seraglia R., Traldi P. Evaluation of IgG glycation levels by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun. Mass Spectrom. 1997, 11:1342-1346.
207. Resemann A., Mayer-Posner F.J., Lapolla A., Fedele D., D'Alpaos M., Traldi P. Further considerations on the use of matrix-assisted laser desorption/ionization mass spectrometry in the analysis of glycated globins. Rapid Commun. Mass Spectrom. 1998, 12:805-807.
208. Lapolla A., Fedele D., Plebani M., Aronica R., Garbeglio M., Seraglia R., D'Alpaos M., Traldi P. Evaluation of glycated globins by matrix-assisted laser desorption/ionization mass spectrometry. Clin. Chem. 1999, 45:288-290.
209. Lapolla A., Fedele D., Plebani M., Garbeglio M., Seraglia R., D'Alpaos M., Arico C.N., Traldi P. Direct evaluation of glycated and glyco-oxidized globins by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun. Mass Spectrom. 1999, 13:8-14.
210. Lapolla A., Fedele D., Garbeglio M., Martano L., Tonani R., Seraglia R., Favretto D., Fedrigo M.A., Traldi P. Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of nonenzymatic glycation of IgG. J. Am. Soc. Mass Spectrom. 2000, 11:153-159.
211. Lapolla A., Tubaro M., Reitano R., Arico N.C., Ragazzi E., Seraglia R., Vogliardi S., Traldi P., Fedele D. The complexity of non-enzymatic glycation product sets of human globins. Diabetologia 2004, 47:1712-1715.
212. Lapolla A., Tubaro M., Fedele D., Reitano R., Arico N.C., Ragazzi E., Seraglia R., Vogliardi S., Traldi P. A matrix-assisted laser desorption/ionization mass spectrometry study of the non-enzymatic glycation products of human globins in diabetes. Rapid Commun. Mass Spectrom. 2005, 19:162-168.
213. Lapolla A., Ragazzi E., Andretta B., Fedele D., Tubaro M., Seraglia R., Molin L., Traldi P. Multivariate analysis of matrix-assisted laser desorption/ionization mass spectrometric data related to glycoxidation products of human globins in nephropathic patients. J. Am. Soc. Mass Spectrom. 2007, 18:1018-1023.
214. Huang P.Y., Lo L.H., Chen Y.C., Lin R.T., Shiea J., Liu C.K. Serum free hemoglobin as a novel potential biomarker for acute ischemic stroke. J. Neurol. 2009, 256:625-631.
215. Watanabe J., Chou K.J., Liao J.C., Miao Y., Meng H.H., Ge H., Grijalva V., Hama S., Kozak K., Buga G., Whitelegge J.P., Lee T.D., Farias-Eisner R., Navab M., Fogelman A.M., Reddy S.T. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J. Biol. Chem. 2007, 282:23698-23707.
216. Lezcano N.E., Odo N., Kutlar A., Brambilla D., Adams R.J. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke 2006, 37:1424-1426.
217. Buttari B., Profumo E., Petrone L., Pietraforte D., Siracusano A., Margutti P., Delunardo F., Ortona E., Minetti M., Salvati B., Rigano R. Free hemoglobin: a dangerous signal for the immune system in patients with carotid atherosclerosis?. Ann. N.Y. Acad. Sci. 2007, 1107:42-50.
218. Rother R.P., Bell L., Hillmen P., Gladwin M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005, 293:1653-1662.
219. Na N., Ouyang J., Taes Y.E., Delanghe J.R. Serum free hemoglobin concentrations in healthy individuals are related to haptoglobin type. Clin. Chem. 2005, 51:1754-1755.
220. Lo L.H., Wu P.C., Wu Y.C., Shiea J. Characterization of human neutrophil peptides (alpha-Defensins) in the tears of dry eye patients. Anal. Methods 2010, 2:1934-1940.
221. Ragazzi E., Vogliardi S., Allegri G., Costa C.V.L., Lise M., Rossi C.R., Seraglia R., Traldi P. Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers. Rapid Commun. Mass Spectrom. 2003, 17:1511-1515.
222. Ferrari L., Seraglia R., Rossi C.R., Bertazzo A., Lise M., Allegri G., Traldi P. Protein profiles in sera of patients with malignant cutaneous melanoma. Rapid Commun. Mass Spectrom. 2000, 14:1149-1154.
223. Lapolla A., Fedele D., Traldi P. Glyco-oxidation in diabetes and related diseases. Clin. Chim. Acta 2005, 357:236-250.
224. Lapolla A., Seraglia R., Molin L., Williams K., Cosma C., Reitano R., Sechi A., Ragazzi E., Traldi P. Low molecular weight proteins in urines from healthy subjects as well as diabetic, nephropathic and diabetic-nephropathic patients: a MALDI study. J. Mass Spectrom. 2009, 44:419-425.
225. Lapolla A., Molin L., Seraglia R., Sechi A., Cosma C., Bonfante L., Chilelli N.C., Ragazzi E., Traldi P. Urinary peptides as a diagnostic tool for renal failure detected by matrix-assisted laser desorption/ionisation mass spectrometry: an evaluation of their clinical significance. Eur. J. Mass Spectrom. 2011, 17:245-253.
226. Zerefos P., Prados J., Kossida S., Kalousis A., Vlahou A. Sample preparation and bioinformatics in MALDI profiling of urinary proteins. J. Chromatogr. B 2007, 853:20-30.
227. Lu C.Y., Su H.H., Chen Y.L., Tseng W.L. Micro extraction to quantitate spermidine and spermine in human urine and blood by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. J. Chromatogr. A 2014, 1326:1-6.
228. Lin S.Y., Shih S.H., Wu D.C., Lee Y.C., Wu C.I., Lo L.H., Shiea J. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for the detection of hemoglobins as the protein biomarkers for fecal occult blood. Rapid Commun. Mass Spectrom. 2007, 21:3311-3316.
229. Wu C.I., Tsai C.C., Lu C.C., Wu P.C., Wu D.C., Lin S.Y., Shiea J. Diagnosis of occult blood in human feces using matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. Clin. Chim. Acta 2007, 384:86-92.
230. P.F. Scholl, P. Demirev, A.B. Feldman, Occult blood detection in biological samples by laser desorption and matrix-assisted laser desorption/ionization mass spectrometry for biomedical applications, US patent 2006, US7,109,038 B2.
231. Duncan M.W., Roder H., Hunsucker S.W. Quantitative matrix-assisted laser desorption/ionization mass spectrometry. Brief. Funct. Genomic. Proteomic. 2008, 7:355-370.
232. Fujiwaki T., Tasaka M., Yamaguchi S. Quantitative evaluation of sphingomyelin and glucosylceramide using matrix-assisted laser desorption ionization time-of-flight mass spectrometry with sphingosylphosphorylcholine as an internal standard practical application to tissues from patients with Niemann-Pick disease types A and C, and Gaucher disease. J. Chromatogr. B 2008, 870:170-176.
233. Fujiwaki T., Tasaka M., Takahashi N., Kobayashi H., Murakami Y., Shimada T., Yamaguchi S. Quantitative evaluation of sphingolipids using delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry with sphingosylphosphorylcholine as an internal standard-practical application to cardiac valves from a patient with Fabry disease. J. Chromatogr. B 2006, 832:97-102.
234. Mims D., Hercules D. Quantification of bile acids directly from urine by MALDI-TOF-MS. Anal. Bioanal. Chem. 2003, 375:609-616.
235. Mims D., Hercules D. Quantification of bile acids directly from plasma by MALDI-TOF-MS. Anal. Bioanal. Chem. 2004, 378:1322-1326.
236. Aresta A., Calvano C.D., Palmisano F., Zambonin C.G., Monaco A., Tornmasi S., Pilato B., Paradiso A. Impact of sample preparation in peptide/protein profiling in human serum by MALDI-TOF mass spectrometry. J. Pharm. Biomed. Anal. 2008, 46:157-164.
237. Kim S.J., Jung H.J., Chung B.C., Choi M.H. Screening analysis of 10 adrenal steroids by matrix-assisted laser desorption ionization-tandem mass spectrometry. Mass Spectrom. Lett. 2011, 2:69-72.
238. Flatley B., Wilmott K.G., Malone P., Cramer R. MALDI MS profiling of post-DRE urine samples highlights the potential of beta-microseminoprotein as a marker for prostatic diseases. Prostate 2014, 74:103-111.
239. Ragazzi E., Pucciarelli S., Seraglia R., Molin L., Agostini M., Lise M., Traldi P., Nitti D. Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer. J. Mass Spectrom. 2006, 41:1546-1553.
240. Seraglia R., Molin L., Tonidandel L., Pucciarelli S., Agostini M., Urso E.D., Bedin C., Quaia M., Nitti D., Traldi P. An investigation on the nature of the peptide at m/z 904, overexpressed in plasma of patients with colorectal cancer and familial adenomatous polyposis. J. Mass Spectrom. 2007, 42:1606-1612.
241. Perez V., Ibernon M., Lopez D., Pastor M.C., Navarro M., Navarro-Munoz M., Bonet J., Romero R. Urinary peptide profiling to differentiate between minimal change disease and focal segmental glomerulosclerosis. PLoS One 2014, 9. e87731.
242. Chu L., Fu G.Z., Meng Q., Zhou H., Zhang M. Identification of urinary biomarkers for type 2 diabetes using bead-based proteomic approach. Diabetes Res. Clin. Pract. 2013, 101:187-193.
243. Conraux L., Pech C., Guerraoui H., Loyaux D., Ferrara P., Guillemot J.C., Meininger V., Pradat P.F., Salachas F., Bruneteau G., Le Forestier N., Lacomblez L. Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling. PLoS One 2013, 8:e79733.
244. Li Z., Lu H.M., Yang J., Zeng X., Zhao L., Li H.D., Liao Q.J., Peng S.P., Zhou M., Wu M.H., Xiang J.J., Wang Y.J., Li G.Y. Analysis of the raw serum peptidomic pattern in glioma patients. Clin. Chim. Acta 2013, 425:221-226.
245. Ying X., Han S.X., Wang J.L., Zhou X., Jin G.H., Jin L., Wang H., Wu L., Zhang J.Y., Zhu Q. Serum peptidome patterns of hepatocellular carcinoma based on magnetic bead separation and mass spectrometry analysis. Diagn. Pathol. 2013, 8:130.
246. Zhu D.X., Wang J., Ren L., Li Y., Xu B., Wei Y., Zhong Y.S., Yu X.Z., Zhai S.Y., Xu J.M., Qin X.Y. Serum proteomic profiling for the early diagnosis of colorectal cancer. J. Cell. Biochem. 2013, 114:448-455.
247. Zhou N., Wang J., Yu Y.Q., Shi J.P., Li X.K., Xu B., Yu Q. Mass spectrum analysis of serum biomarker proteins from patients with schizophrenia. Biomed. Chromatogr. 2014, 28:654-659.
248. Graterol F., Navarro-Munoz M., Ibernon M., Lopez D., Troya M.I., Perez V., Bonet J., Romero R. Poor histological lesions in IgA nephropathy may be reflected in blood and urine peptide profiling. BMC Nephrol. 2013, 14:82.
249. Kikkawa S., Sogawa K., Satoh M., Umemura H., Kodera Y., Matsushita K., Tomonaga T., Miyazaki M., Yokosuka O., Nomura F. Identification of a novel biomarker for biliary tract cancer using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Int. J. Proteomics 2012, 2012:108609.
250. Nanni P., Parisi D., Roda G., Casale M., Belluzzi A., Roda E., Mayer L., Roda A. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun. Mass Spectrom. 2007, 21:4142-4148.
251. Wei P., Kuo W.P., Chen F., Hua H. Diagnostic model of saliva peptide finger print analysis of primary Sjogren's syndrome patients by using weak cation exchange magnetic beads. Biosci. Rep. 2013, 33:567-573.
252. Wang L., Liu H.Y., Shi H.H., Lang J.H., Sun W. Urine peptide patterns for non-invasive diagnosis of endometriosis: a preliminary prospective study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014, 177:23-28.
253. Sparbier K., Wenzel T., Dihazi H., Blaschke S., Muller G.A., Deelder A., Flad T., Kostrzewa M. Immuno-MALDI-TOF MS: new perspectives for clinical applications of mass spectrometry. Proteomics 2009, 9:1442-1450.
254. Reid J.D., Holmes D.T., Mason D.R., Shah B., Borchers C.H. Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J. Am. Soc. Mass Spectrom. 2010, 21:1680-1686.
255. Camenzind A.G., van der Gugten J.G., Popp R., Holmes D.T., Borchers C.H. Development and evaluation of an immuno-MALDI (iMALDI) assay for angiotensin I and the diagnosis of secondary hypertension. Clin. Proteomics 2013, 10:20.
256. Shimada T., Toyama A., Aoki C., Aoki Y., Tanaka K., Sato T.A. Direct antigen detection from immunoprecipitated beads using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; a new method for immunobeads-mass spectrometry (iMS). Rapid Commun. Mass Spectrom. 2011, 25:3521-3526.
257. Kaneko N., Yamamoto R., Sato T.A., Tanaka K. Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2014, 90:104-117.
258. Qiao L., Liu B., Girault H.H. Nanomaterial-assisted laser desorption ionization for mass spectrometry-based biomedical analysis. Nanomedicine 2010, 5:1641-1652.
259. Terracciano R., Pasqua L., Casadonte F., Frasca S., Preiano M., Falcone D., Savino R. Derivatized mesoporous silica beads for MALDI-TOF MS profiling of human plasma and urine. Bioconjug. Chem. 2009, 20:913-923.
260. Fan J., Niu S., Dong A., Shi J., Wu H.J., Fine D.H., Tian Y., Zhou C., Liu X., Sun T., Anderson G.J., Ferrari M., Nie G., Hu Y., Zhao Y. Nanopore film based enrichment and quantification of low abundance hepcidin from human bodily fluids. Nanomedicine 2014, 10:879-888.
261. Tan J., Zhao W.J., Yu J.K., Ma S., Sailor M.J., Wu J.M. Capture, enrichment, and mass spectrometric detection of low-molecular-weight biomarkers with nanoporous silicon microparticles. Adv. Healthc. Mater. 2012, 1:742-750.
262. Qiao L., Roussel C., Wan J., Yang P., Girault H.H., Liu B. Specific on-plate enrichment of phosphorylated peptides for direct MALDI-TOF MS analysis. J. Proteome Res. 2007, 6:4763-4769.
263. Zhao M., Deng C., Zhang X. Synthesis of polydopamine-coated magnetic graphene for Cu(2+) immobilization and application to the enrichment of low-concentration peptides for mass spectrometry analysis. ACS Appl. Mater. Interfaces 2013, 5:13104-13112.
264. Lin P.C., Tseng M.C., Su A.K., Chen Y.J., Lin C.C. Functionalized magnetic nanoparticles for small-molecule isolation, identification, and quantification. Anal. Chem. 2007, 79:3401-3408.
265. Wan D., Gao M., Wang Y., Zhang P., Zhang X. A rapid and simple separation and direct detection of glutathione by gold nanoparticles and graphene-based MALDI-TOF-MS. J. Sep. Sci. 2013, 36:629-635.
266. Li Y., Lin H., Deng C., Yang P., Zhang X. Highly selective and rapid enrichment of phosphorylated peptides using gallium oxide-coated magnetic microspheres for MALDI-TOF-MS and nano-LC-ESI-MS/MS/MS analysis. Proteomics 2008, 8:238-249.
267. Zhang X., Zhu S., Deng C., Zhang X. Highly sensitive thrombin detection by matrix assisted laser desorption ionization-time of flight mass spectrometry with aptamer functionalized core-shell Fe(3)O(4)@C@Au magnetic microspheres. Talanta 2012, 88:295-302.
268. Zou X., Liu D., Zhong L., Yang B., Lou Y., Hu B., Yin Y. Highly specific capture and direct MALDI-MS analysis of phosphorylated peptides using novel multifunctional chitosan-GMA-IDA-Fe (III) nanosphere. Anal. Bioanal. Chem. 2011, 401:1251-1261.
269. Ferreira J.A., Daniel-da-Silva A.L., Alves R.M., Duarte D., Vieira I., Santos L.L., Vitorino R., Amado F. Synthesis and optimization of lectin functionalized nanoprobes for the selective recovery of glycoproteins from human body fluids. Anal. Chem. 2011, 83:7035-7043.
270. Hinterwirth H., Stubiger G., Lindner W., Lammerhofer M. Gold nanoparticle-conjugated anti-oxidized low-density lipoprotein antibodies for targeted lipidomics of oxidative stress biomarkers. Anal. Chem. 2013, 85:8376-8384.
271. Xiong Y., Deng C., Zhang X. Development of aptamer-conjugated magnetic graphene/gold nanoparticle hybrid nanocomposites for specific enrichment and rapid analysis of thrombin by MALDI-TOF MS. Talanta 2014, 129:282-289.
272. Ara M.N., Matsuda T., Hyodo M., Sakurai Y., Hatakeyama H., Ohga N., Hida K., Harashima H. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells. Biomaterials 2014, 35:7110-7120.
273. Li R., Jin C.A., Mirkin R.L. Letsinger, multiple thiol-anchor capped DNA-gold nanoparticle conjugates. Nucleic Acids Res. 2002, 30:1558-1562.
274. Qiu F., Jiang D., Ding Y., Zhu J., Huang L.L. Monolayer-barcoded nanoparticles for on-chip DNA hybridization assay. Angew. Chem. 2008, 47:5009-5012.
275. Chou T.C., Hsu W., Wang C.H., Chen Y.J., Fang J.M. Rapid and specific influenza virus detection by functionalized magnetic nanoparticles and mass spectrometry. J. Nanobiotechnol. 2011, 9:52.
276. Teng C.H., Ho K.C., Lin Y.S., Chen Y.C. Gold nanoparticles as selective and concentrating probes for samples in MALDI MS analysis. Anal. Chem. 2004, 76:4337-4342.
277. Qiao L., Bi H., Busnel J.M., Liu B., Girault H.H. In-source photocatalytic reduction of disulfide bonds during laser desorption ionization. Chem. Commun. 2008, 6357-6359.
278. Qiao L., Bi H., Busnel J.M., Waser J., Yang P., Girault H.H., Liu B. Photocatalytic redox reactions for in-source peptide fragmentation. Chemistry 2009, 15:6711-6717.
279. Pietronave S., Iafisco M., Locarno D., Rimondini L., Maria Prat M. Functionalized nanomaterials for diagnosis and therapy of cancer. J. Appl. Biomater. Biomech. 2009, 7:77-89.
280. Yang F., Jin C., Subedi S., Lee C.L., Wang Q., Jiang Y., Li J., Di Y., Fu D. Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treat. Rev. 2012, 38:566-579.
281. Kailasa S.K., Wu H.F. Surface modified silver selinide nanoparticles as extracting probes to improve peptide/protein detection via nanoparticles-based liquid phase microextraction coupled with MALDI mass spectrometry. Talanta 2010, 83:527-534.
282. Shastri L., Kailasa S.K., Wu H.F. Nanoparticle-single drop microextraction as multifunctional and sensitive nanoprobes: binary matrix approach for gold nanoparticles modified with (4-mercaptophenyliminomethyl)-2-methoxyphenol for peptide and protein analysis in MALDI-TOF MS. Talanta 2010, 81:1176-1182.
283. Forde C.E., McCutchen-Maloney S.L. Characterization of transcription factors by mass spectrometry and the role of SELDI-MS. Mass Spectrom. Rev. 2002, 21:419-439.
284. Tang N., Tornatore P., Weinberger S.R. Current developments in SELDI affinity technology. Mass Spectrom. Rev. 2004, 23:34-44.
285. Wright G.L. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev. Mol. Diagn. 2002, 2:549-563.
286. Yip T.T., Lomas L. SELDI ProteinChip (R) array in oncoproteomic research. Technol. Cancer Res. Treat. 2002, 1:273-279.
287. Gretzer M.B., Partin A.W., Chan D.W., Veltri R.W. Modern tumor marker discovery in urology: surface enhanced laser desorption and ionization (SELDI). Rev. Urol. 2003, 5:81-89.
288. Clarke C.H., Buckley J.A., Fung E.T. SELDI-TOF-MS proteomics of breast cancer. Clin. Chem. Lab. Med. 2005, 43:1314-1320.
289. Garrisi V.M., Abbate I., Quaranta M., Mangia A., Tommasi S., Paradiso A. SELDI-TOF serum proteomics and breast cancer: which perspective?. Expert Rev. Proteomics 2008, 5:779-785.
290. Whelan L.C., Power K.A.R., McDowell D.T., Kennedy J., Gallagher W.M. Applications of SELDI-MS technology in oncology. J. Cell. Mol. Med. 2008, 12:1535-1547.
291. Fung E., Diamond D., Simonsesn A.H., Weinberger S.R. The use of SELDI ProteinChip array technology in renal disease research. Methods Mol. Med. 2003, 86:295-312.
292. Liu C.B. The application of SELDI-TOF-MS in clinical diagnosis of cancers. J. Biomed. Biotechnol. 2011, 2011:245821.
293. Seibert V., Ebert M.P., Buschmann T. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief. Funct. Genomic. Proteomic. 2005, 4:16-26.
294. Shintani S., Hamakawa H., Ueyama Y., Hatori M., Toyoshima T. Identification of a truncated cystatin SA-I as a saliva biomarker for oral squamous cell carcinoma using the SELDI ProteinChip platform. Int. J. Oral Maxillofac. Surg. 2010, 39:68-74.
295. He J.B., Gornbein J., Shen D., Lu M., Rovai L.E., Shau H., Katz J., Whitelegge J.P., Faull K.F., Chang H.R. Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry. Int. J. Oncol. 2007, 30:145-154.
296. Poon T.C.W. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev. Proteomics 2007, 4:51-65.
297. Chen L., Fatima S., Peng J.R., Leng X.S. SELDI protein chip technology for the detection of serum biomarkers for liver disease. Protein Pept. Lett. 2009, 16:467-472.
298. Castagna A., Campostrini N., Zaninotto F., Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J. Proteomics 2010, 73:527-536.
299. Reis H.J., Wang L., Verano-Braga T., Pimenta A.M.C., Kalman J., Bogats G., Babik B., Vieira L.B., Teixeira A.L., Mukhamedyarov M.A., Zefirov A.L., Kiyasov A.P., Rizvanov A.A., Matin K., Palotas M., Guimaraes M.M., Ferreira C.N., Yalvac M.E., Janka Z., Palotas A. Evaluation of post-surgical cognitive function and protein fingerprints in the cerebro-spinal fluid utilizing surface-enhanced laser desorption/ionization time-of-flight mass-spectrometry (SELDI-TOF MS) after coronary artery bypass grafting: review of proteomic analytic tools and introducing a new syndrome. Curr. Med. Chem. 2011, 18:1019-1037.
300. Papale M., Pedicillo M.C., Di Paolo S., Thatcher B.J., Lo Muzio L., Bufo P., Rocchetti T., Centra M., Ranieri E., Gesualdo L. Saliva analysis by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF/MS): from sample collection to data analysis. Clin. Chem. Lab. Med. 2008, 46:89-99.
301. Schipper R., Loof A., de Groot J., Harthoorn L., van Heerde W., Dransfield E. Salivary protein/peptide profiling with SELDI-TOF-MS. Ann. N.Y. Acad. Sci. 2007, 1098:498-503.
302. Grus F.H., Podust V.N., Bruns K., Lackner K., Fu S.Y., Dalmasso E.A., Wirthlin A., Pfeiffer N. SELDI-TOF-MS ProteinChip array profiling of tears from patients with dry eye. Invest. Ophthalmol. Vis. Sci. 2005, 46:863-876.
303. Liu Z., Yuan Z., Zhao Q. SELDI-TOF-MS proteomic profiling of serum, urine, and amniotic fluid in neural tube defects. PLoS One 2014, 9:e103276.
304. Deng B.P., Dong Z.G., Liu Y.G., Wang C.N., Liu J., Wang C.X., Qu X. Effects of pretreatment protocols on human amniotic fluid protein profiling with SELDI-TOF MS using protein chips and magnetic beads. Clin. Chim. Acta 2010, 411:1051-1057.
305. Koomen J.M., Zhao H., Li D., Abbruzzese J., Baggerly K., Kobayashi R. Diagnostic protein discovery using proteolytic peptide targeting and identification. Rapid Commun. Mass Spectrom. 2004, 18:2537-2548.
306. Dekker L.J., Dalebout J.C., Siccama I., Jenster G., Sillevis Smitt P.A., Luider T.M. A new method to analyze matrix-assisted laser desorption/ionization time-of-flight peptide profiling mass spectra. Rapid Commun. Mass Spectrom. 2005, 19:865-870.
307. Dekker L.J., Boogerd W., Stockhammer G., Dalebout J.C., Siccama I., Zheng P., Bonfrer J.M., Verschuuren J.J., Jenster G., Verbeek M.M., Luider T.M., Smitt P.A. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol. Cell. Proteomics 2005, 4:1341-1349.
308. Stoop M.P., Dekker L.J., Titulaer M.K., Burgers P.C., Sillevis Smitt P.A., Luider T.M., Hintzen R.Q. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008, 8:1576-1585.
309. Ahn Y.H., Kim K.H., Shin P.M., Ji E.S., Kim H., Yoo J.S. Identification of low-abundance cancer biomarker candidate TIMP1 from serum with lectin fractionation and peptide affinity enrichment by ultrahigh-resolution mass spectrometry. Anal. Chem. 2012, 84:1425-1431.
310. Hollemeyer K., Jager S., Altmeyer W., Heinzle E. Proteolytic peptide patterns as indicators for fungal infections and nonfungal affections of human nails measured by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Biochem. 2005, 338:326-331.
311. Cho Y.T., Chen C.W., Chen M.P., Hu J.L., Su H., Shiea J., Wu W.J., Wu D.C. Diagnosis of albuminuria by tryptic digestion and matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. Clin. Chim. Acta 2013, 420:76-81.
312. Szanto I., Mark L., Bona A., Maasz G., Sandor B., Gelencser G., Turi Z., Gallyas F. High-throughput screening of saliva for early detection of oral cancer: a pilot study. Technol. Cancer Res. Treat. 2012, 11:181-188.
313. Lo L.H., Huang T.L., Shiea J. Acid hydrolysis followed by matrix-assisted laser desorption/ionization mass spectrometry for the rapid diagnosis of serum protein biomarkers in patients with major depression. Rapid Commun. Mass Spectrom. 2009, 23:589-598.
314. Xu C., Pranovich A., Vahasalo L., Hemming J., Holmbom B., Schols H.A., Willfor S. Kinetics of acid hydrolysis of water-soluble spruce O-acetyl galactoglucomannans. J. Agric. Food Chem. 2008, 56:2429-2435.
315. Lee B.S., Krishnanchettiar S., Lateef S.S., Lateef N.S., Gupta S. Characterization of oligosaccharide moieties of intact glycoproteins by microwave-assisted partial acid hydrolysis and mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19:2629-2635.
316. Lee B.S., Krishnanchettiar S., Lateef S.S., Gupta S. Characterization of oligosaccharide moieties of glycopeptides by microwave-assisted partial acid hydrolysis and mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19:1545-1550.
317. Mirgorodskaya O.A., Korner R., Novikov A., Roepstorff P. Absolute quantitation of proteins by a combination of acid hydrolysis and matrix-assisted laser desorption/ionization mass spectrometry. Anal. Chem. 2004, 76:3569-3575.
318. Vorm O., Roepstorff P. Peptide sequence information derived by partial acid hydrolysis and matrix-assisted laser desorption/ionization mass spectrometry. Biol. Mass Spectrom. 1994, 23:734-740.
319. Knierman M.D., Coligan J.E., Parker K.C. Peptide fingerprints after partial acid hydrolysis: analysis by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun. Mass Spectrom. 1994, 8:1007-1010.
320. Guo N., Higgins T.N. MALDI-TOF MS/microwave-assisted acid hydrolysis identification of HbG Coushatta. Clin. Biochem. 2009, 42:99-107.